From the Journals

Rare clear cell papillary RCC has indolent course


 

FROM JOURNAL OF THE CHINESE MEDICAL SOCIETY

The investigators did not report a study funding source. They reported having no conflicts of interest relevant to the subject matter or materials discussed in the article.

SOURCE: Chen W-J et al. J Chinese Med Assoc. 2018 July 20. doi: 10.1016/j.jcma.2018.04.005.

Pages

Recommended Reading

Company discontinues phase 3 ADAPT for mRCC
MDedge Hematology and Oncology
Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma
MDedge Hematology and Oncology
Checkpoint inhibitors get to patients quickly
MDedge Hematology and Oncology
Is cancer immunotherapy more effective in men than women?
MDedge Hematology and Oncology
IMDC model mirrors mRCC clinical outcomes
MDedge Hematology and Oncology
Protein activation could predict renal cell carcinoma recurrence
MDedge Hematology and Oncology
KEYNOTE-427: Pembrolizumab monotherapy shows promise in accRCC
MDedge Hematology and Oncology
Many actionable mutations may be missed in current testing of advanced RCC
MDedge Hematology and Oncology
Gene assays reveal some ‘unknown primary’ cancers as RCC
MDedge Hematology and Oncology
Conditional OS estimates show upfront TKI benefit in mRCC
MDedge Hematology and Oncology